Liquidia Corporation (LQDA)
NASDAQ: LQDA · IEX Real-Time Price · USD
11.83
-0.21 (-1.74%)
At close: Jul 2, 2024, 4:00 PM
11.84
+0.01 (0.08%)
After-hours: Jul 2, 2024, 6:43 PM EDT
Liquidia Revenue
Liquidia had revenue of $15.97M in the twelve months ending March 31, 2024, down -5.72% year-over-year. Revenue in the quarter ending March 31, 2024 was $2.97M, a -33.85% decrease year-over-year. In the year 2023, Liquidia had annual revenue of $17.49M with 9.75% growth.
Revenue (ttm)
$15.97M
Revenue Growth
-5.72%
P/S Ratio
56.62
Revenue / Employee
$110,117
Employees
145
Market Cap
903.98M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 17.49M | 1.55M | 9.75% |
Dec 31, 2022 | 15.94M | 3.08M | 23.98% |
Dec 31, 2021 | 12.85M | 12.11M | 1,637.77% |
Dec 31, 2020 | 739.63K | -7.33M | -90.84% |
Dec 31, 2019 | 8.07M | 5.37M | 198.20% |
Dec 31, 2018 | 2.71M | -4.55M | -62.70% |
Dec 31, 2017 | 7.26M | -5.96M | -45.08% |
Dec 31, 2016 | 13.22M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
OPKO Health | 799.60M |
Avanos Medical | 680.10M |
Maravai LifeSciences Holdings | 274.10M |
BioLife Solutions | 137.30M |
Cronos Group | 93.03M |
Simulations Plus | 64.67M |
Tango Therapeutics | 37.23M |
Silence Therapeutics | 33.86M |
LQDA News
- 14 days ago - Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH) - GlobeNewsWire
- 7 weeks ago - Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD - GlobeNewsWire
- 3 months ago - Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 3 months ago - Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder - GlobeNewsWire
- 3 months ago - Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024 - GlobeNewsWire
- 4 months ago - United Therapeutics starts litigation with FDA for allowing Liquidia's drug application - Reuters